Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.


Sai Life Sciences strengthens discovery leadership

Sai Life Sciences, a leading global contract research, development, and manufacturing organization, announces the addition of two seasoned professionals to its leadership team.

Dr Atul Tiwari joins as Vice President – Discovery Strategy & Business, while Dr Santosh Kulkarni takes on the role of Vice President – Medicinal Chemistry. Their wealth of experience promises to drive Sai Life Sciences to new heights in drug discovery and development.

Atul will lead strategy for Integrated Drug Discovery (IDD) programs and will develop short- and long-term strategies for business growth apart from establishing new collaborations and interfacing with clients. A PhD in Biochemistry from NDRI, Karnal, Atul brings nearly 24 years of experience in drug discovery and development working across diverse therapeutic areas such as Oncology, Immuno-oncology, Metabolic Disorders CNS, Autoimmune disorders, and rare indications, from target ID/validation to clinical candidate, and drug modalities- small molecules; PROTACs; antibodies; ADCs; Oligonucleotides; Cell Therapies (iPSCs). 

Santosh will be leading the medicinal chemistry team in discovery services. Holding a PhD in Chemistry from ICT (formerly UDCT) and with post-doctoral research experience at the National Institutes of Health (NIH), Santosh has over two decades of expertise in drug discovery. His expertise spans various modalities, including small molecules, PROTACs, ADCs, and peptides. He has worked with cross-functional teams in collaborations with Biology, PRD, Formulation, Chemical Development and Manufacturing to lead integrated drug discovery programs from early hit discovery to candidate nomination and further towards development in clinical phases.

In recent years, Sai’s discovery services have been witnessing a steep growth and the addition of Dr Atul Tiwari and Dr Santosh Kulkarni to Sai Life Sciences' leadership team will fortify the organization's capabilities in medicinal chemistry and discovery strategy. The company looks forward to achieving new milestones and fostering collaborative efforts that will shape the future of pharmaceutical advancements.

Share article

More News


Sai Life Sciences releases its Sustainability Report 2023

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), released its Sustainability Report 2022-2023. Developed in accordance with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, the fourth edition of the Sustainability report is based on the theme ‘Steadfast on Sustainability,’ and it articulates the company’s commitment to sustainability […]
Read more


Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), has expanded its DMPK capabilities. The expansion comprises the addition of 25,000 sq. ft. of state-of-the-art labs equipped with cutting-edge instrumentation enabling high-end automation. Complementing the expansion has been […]
Read more


Sai Life Sciences wins Gold in Brandon Hall Group’s Excellence in Technology Awards

Sai Life Sciences won Gold in Brandon Hall Group’s Excellence in Technology Awards in the ‘Best Advance in Content Authoring Technology’ category. Sai Life Sciences was recognized for the use of UL Create Tool, an easy-to-use, cloud-based authoring tool from UL Solutions, for making the learning process seamless and effective for all. The company utilized […]
Read more


Sai Life Silver Jubilee year

Sai Life Sciences enters its Silver Jubilee year; surpasses vision of 25 commercial molecules by 2025

Sai Life Sciences entered its Silver Jubilee year with aplomb, surpassing its vision of supporting global innovator partners in bringing 25 new medicines to market by 2025. The company crossed this milestone two years ahead of schedule and is poised to sustain this momentum on the back of a strong portfolio of molecules at various […]
Read more



Sai Life Sciences joins Science Based Targets initiative (SBTi), commits to fight climate change with Science

To help combat climate change, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), announced joining Science Based Targets initiative (SBTi), a global body enabling businesses to set ambitious emission reduction targets in line with the latest climate science. Accordingly, it has committed to set near-term company-wide emission reductions in line with […]
Read more